Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Chronic Granulomatous Disease

Blood & Immune

Chronic Granulomatous Disease (CGD) Clinical Trials

Also called CGD, NADPH oxidase deficiency, phagocytic dysfunction

Chronic granulomatous disease (CGD) is a rare inherited immunodeficiency caused by mutations affecting the NADPH oxidase complex in phagocytes, preventing production of reactive oxygen species critical for killing certain pathogens. The X-linked form, caused by changes in the CYBB gene, accounts for about 70% of cases, according to MedlinePlus Genetics, and mostly affects males, while autosomal recessive variants involve mutations in other NADPH oxidase subunits including CYBA, NCF1, NCF2, and NCF4.

In plain words, chronic granulomatous disease is a rare inherited immune problem where certain white blood cells cannot kill some germs. People with it get repeated serious infections from bacteria and fungi, along with lumps of swollen tissue in organs like the lungs.

Get an email when new Chronic Granulomatous Disease trials open or the FDA decides. Get alerts

Chronic Granulomatous Disease

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 4 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines1

Actimmune

Chronic Granulomatous Disease has 1 FDA-approved medicine, 11 open or active clinical trials (10 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Chronic Granulomatous Disease

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Chronic Granulomatous Disease

Affected neutrophils and macrophages cannot produce the respiratory burst necessary to kill catalase-positive organisms including Staphylococcus aureus, Serratia, Nocardia, Aspergillus, and Burkholderia cepacia.

Keep reading about Chronic Granulomatous Disease

Patients typically develop recurrent severe bacterial and fungal infections starting in infancy or early childhood, including suppurative lymphadenitis, hepatic and splenic abscesses, chronic pneumonia with granuloma formation, osteomyelitis, and skin infections. Excessive granuloma formation at infection sites and in draining lymph nodes can cause significant obstruction of the GI tract, genitourinary system, and respiratory tract. Prognosis has dramatically improved with prophylactic antimicrobials and interferon-gamma therapy; median survival now exceeds 40 years.

What are the symptoms of Chronic Granulomatous Disease?

These are common symptoms of Chronic Granulomatous Disease, and how strong they are varies from person to person.

  • Severe, recurrent infections (bacteria and fungi)
  • Granuloma formation affecting multiple organs
  • Lymphadenitis and hepatosplenomegaly
  • Lung infections and granulomas
  • GI complications including obstruction
  • Osteomyelitis and skin infections

Who gets Chronic Granulomatous Disease?

X-linked CGD, which mostly affects boys, accounts for about 70% of cases, according to MedlinePlus Genetics, and usually shows up in infancy or early childhood. Autosomal recessive forms affect both males and females equally and show equal distribution across all ethnic populations.

Geographic variation is minimal; however, certain populations show increased carrier frequencies due to founder effects. Manifestations typically begin in infancy (first months to years of life), though some patients with specific mutations demonstrate delayed presentation. Approximately 5-10% of CGD cases are detected in adulthood.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Chronic Granulomatous Disease?

There is currently 1 FDA-approved medication for Chronic Granulomatous Disease.

interferon gamma-1b
Amgen
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Chronic Granulomatous Disease treatment

Charity funds and drugmaker programs for Chronic Granulomatous Disease, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · Good Days
    Chronic Granulomatous Disease fund
    Open

    Pays for: Copays for FDA-approved medications (plus travel for some funds), up to $10,000 per year. Requires health insurance (any kind).

    The foundation says: “Program Status: open.”
  • From a charity · The Assistance Fund
    Chronic Granulomatous Disease (CGD) fund
    Open

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on October 26, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Chronic Granulomatous Disease, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Chronic Granulomatous Disease

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Chronic Granulomatous Disease resources

Reputable organizations and medical references for learning more about Chronic Granulomatous Disease, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Chronic Granulomatous Disease

Use this Chronic Granulomatous Disease clinical trial finder to see the 10 studies recruiting patients and 1 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 8 test a treatment and 3 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

11 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 1Recently updatedNCT05189925

NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

Intervention: gp91 Grans

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Background:

Ages 18 Years to 75 Years1 location
Started Jul 2022Updated 1 week agoEst. Jul 2027 (~7 months)
RecruitingObservational study, no treatment givenRecently updatedNCT00128973

Evaluation of Patients With Immune Function Abnormalities

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation. This may include inherited conditions, such as X-linked severe combined immunodeficiency (XSCID), chronic granulomatous disease (CGD), and leuk...

Ages not specified1 location
Started Sep 2005Updated 1 week agoCompletion date not listed
RecruitingObservational study, no treatment givenRecently updatedNCT00001405

Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

The research goal of this study is to obtain CD34+ hematopoietic stem cells (HSC) from peripheral blood and/or bone marrow, and Mononuclear Cells (lymphocytes and monocytes), and granulocytes (grans) from peripheral blood that will be used in the laboratory and/or in the clinic t...

Ages 18 Years to 70 Years1 location
Started Feb 1994Updated 1 week agoCompletion date not listed
RecruitingTreatment trialPhase 1/2Recently updatedNCT06325709

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Intervention: Campath, Sirolimus, Base-edited hematopoietic stem and progenitor cells, Busulfan, Palifermin, Filgrastim, Plerixafor

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Background:

Ages 18 Years to 75 Years1 location
Started Apr 2024Updated 1 week agoEst. Dec 2032 (~6y 1m)
Not yet recruitingTreatment trialRecently updatedNCT03645486

Lentiviral Gene Therapy for CGD

Intervention: Infusion of lentiviral TYF-CGD-modified autologous stem cells

Sponsor: Shenzhen Geno-Immune Medical Institute

This is a Phase I/II clinical trial of gene therapy for treating Chronic Granulomatous Disease using a high-safety, high-efficiency, self-inactivating lentiviral vector TYF to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the TYF-CGD gene transfer clinical protocol.

Ages not specified1 location
Expected to start Jul 2027Updated 2 weeks agoEst. Jun 2028 (~1y 7m)
Find Chronic Granulomatous Disease trials near you, ranked by distance →
Active trial locations52 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+44 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Chronic Granulomatous Disease trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Chronic Granulomatous Disease foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Chronic Granulomatous Disease patient communities

Facebook groups, Reddit communities and YouTube channels where Chronic Granulomatous Disease patients, caregivers and advocacy groups talk.

Companies developing Chronic Granulomatous Disease treatments

Drugmakers that list Chronic Granulomatous Disease in their rare disease portfolio, 2 in all.

Questions people ask about Chronic Granulomatous Disease